PTPA and acute lymphoblastic leukemia: Although the paucity of data regarding the involvement of PP2A or SET in ALL could not draw any conclusive remark, the presence of the Ph1 chromosome in a cohort of patients with ALL would allow in the next future to investigate the role of PADs in this subgroup of patients and to test whether the inclusion of PADs in standard treatment schedule may add any advantage in cure rate and survivals.